Docon Technologies Sells 9.9% Stake in Thyrocare for Rs 986 Crore

Docon Technologies, a key promoter of Thyrocare Technologies Ltd, has divested a 9.9% stake in the diagnostics company, raising Rs 986 crore through a series of transactions on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). The sale, executed on Thursday, involved both block and bulk deals, impacting the company's shareholding dynamics.

Details of the Stake Sale

The transaction involved the sale of 1,57,69,696 equity shares. More than 1.31 crore shares were sold through block deals, while an additional 10 lakh shares were transacted via bulk deals on the NSE. Furthermore, 16.01 lakh shares changed hands through a bulk deal on the BSE. The shares were sold within a price range of Rs 624 to Rs 631.71 per share, culminating in a total transaction value of Rs 985.86 crore.

Post-transaction, Docon's stake in Thyrocare has decreased from 60.92% to 51.02%, marking a significant shift in its ownership structure.

Investor Interest and Market Reaction

The stake sale attracted interest from a range of institutional investors, including HSBC Mutual Fund, DSP Mutual Fund, ICICI Prudential Mutual Fund, Aditya Birla Sun Life Mutual Fund, WhiteOak Capital Mutual Fund, and ITI Mutual Fund. Life insurance companies such as Kotak Mahindra Life Insurance and Tata AIA Life Insurance also participated. Additionally, global investors like Morgan Stanley, Citigroup Global Markets, HBM Healthcare Investments (Cayman), and the sovereign wealth fund Kuwait Investment Authority were involved through block deals on the NSE.

Following the announcement of the sale, Thyrocare Technologies' shares saw a positive market response. On Friday, the shares rose nearly 3% to Rs 621.95 on the NSE and over 2% to Rs 622 on the BSE.

Historical Context and Future Implications

This recent sale follows Docon Technologies' previous divestment of a 10% stake in Thyrocare for Rs 667 crore in October of the prior year. The back-to-back sales indicate a strategic move by Docon to recalibrate its investment in the diagnostics firm.

Thyrocare Technologies, known for its diagnostic services across India, continues to be a focal point for institutional investors, reflecting the growing interest in the healthcare sector. The infusion of capital from such sales could potentially fuel further expansion and innovation within the company.